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Some of the clinically most important viruses persist in the human host after acute 
infection. In this situation, the host immune system and the viral pathogen attempt 
to establish an equilibrium. At best, overt disease is avoided. This attempt may fail, 
however, resulting in eventual loss of viral control or inadequate immune regulation. 
Consequently, direct virus-induced tissue damage or immunopathology may occur. The 
cluster of differentiation 1 (CD1) family of non-classical major histocompatibility complex 
class I molecules are known to present hydrophobic, primarily lipid antigens. There is 
ample evidence that both CD1-dependent and CD1-independent mechanisms activate 
CD1-restricted T cells during persistent virus infections. Sophisticated viral mechanisms 
subvert these immune responses and help the pathogens to avoid clearance from the 
host organism. CD1-restricted T cells are not only crucial for the antiviral host defense 
but may also contribute to tissue damage. This review highlights the two edged role of 
CD1-restricted T cells in persistent virus infections and summarizes the viral immune 
evasion mechanisms that target these fascinating immune cells.
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iNTRODUCTiON
The majority of virus infections are self-limiting. Immunocompetent hosts often eliminate the invad-
ing pathogen without causing permanent tissue damage. Some viruses, however, can resist clearance, 
and persist in the host organism in the face of intact antiviral immune responses. Persisting viruses 
belong to different RNA and DNA virus families and represent a global threat to human health (1). 
As a strategy for persistence, they utilize chronic infection, latency, or both. Chronic infection is 
characterized by the continuous generation of infectious virus particles as observed during infection 
with hepatitis B virus (HBV) (2) or hepatitis C virus (HCV) (3). During latent infection, production 
of viral progeny is put on ice while the viral genome replicates with the host DNA. In the latent 
stage, viruses are nearly invisible for the host defense but can reinitiate production of infectious 
viral particles. Primarily human papillomavirus (HPV) (4) and the human herpesviruses (HHVs) 
(5) establish latency. Human immunodeficiency virus (HIV) establishes both chronic and latent 
infection (6). The immunological challenges associated with persisting virus infections are distinct 
from acute self-limiting infections (7).
Virus persistence is largely the result of an evolutionary arms race between the host immune 
system and viral immune evasion mechanisms (8). For example, persisting viruses have learned 
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to subvert the attack of cytotoxic T cells, which recognize viral 
peptides presented by major histocompatibility complex (MHC) 
class I molecules (9). Cluster of differentiation 1 (CD1) molecules 
are structurally related to MHC class I heavy chain molecules 
and also associate with β2-microglobulin (10–12). They are 
expressed in mammals, birds and reptiles, although isoforms, 
antigen-binding sites, recycling motifs and genomic locations are 
not well conserved (13, 14). In striking contrast to MHC class 
I molecules, CD1 molecules are non-polymorphic and present 
hydrophobic, primarily lipid antigens to specialized T  cells 
(15, 16). These CD1-restricted T cells are at the frontline of the 
human immune response against pathogenic microbes includ-
ing viruses (17). In this review, we discuss lipid-driven T  cell 
responses during persistent virus infections and the correspond-
ing viral counter measures.
CD1-ReSTRiCTeD T CeLLS
In humans CD1 molecules are divided into group 1 (CD1a, 
CD1b, CD1c) and group 2 (CD1d) by sequence homology (18). 
Group 1 genes can be induced in a coordinated fashion primarily 
in professional antigen-presenting cells such as dendritic cells 
(DCs). In contrast, CD1d is constitutively expressed in a wider 
range of hematopoietic and non- hematopoietic cells (19). CD1-
restricted T cells belong to the “unconventional” T cells that do 
not recognize MHC-bound peptides, and which often show rapid 
effector functions and orchestrate other immune cells (20–23).
Group 1 CD1-restricted T cells express diverse αβ T-cell recep-
tors (TCRs). They can undergo clonal expansion in the periphery 
after recognition of stimulatory self-lipids or exogenous lipid 
antigens derived from bacteria such as Mycobacterium tuberculo-
sis (24–26). CD1d-restricted T cells are referred to as natural killer 
T (NKT) cells because they usually—but not always—express 
NK1.1 (CD161), a NK cell activating C-type lectin. These cells 
are further divided into type 1 and type 2 NKT cells.
Type 1 NKT or invariant NKT (iNKT) cells express a semi-
invariant αβ TCR, defined by expression of the Vα14-Jα18 
TCR in mice and Vα24-Jα18 TCR in humans. They have been 
analyzed in great detail [recently reviewed in Ref. (17, 27–30)]. 
The iNKT cells are optimally stimulated by α-galactosylceramide 
(αGalCer), a glycolipid antigen derived from marine sponge (31). 
Physiological ligands include cellular and microbial lipids (32). It 
has been shown that iNKT cells contribute to antiviral responses 
although the relevant lipid antigens have not yet been defined 
[recently reviewed in Ref. (33–37)].
Type 2 NKT  cells are not stimulated by αGalCer and show 
much more TCR sequence variability than iNKT cells (38–40). 
They are more prevalent in humans than iNKT cells, show features 
of both conventional T cells and iNKT cells and also influence the 
outcome of infections with persisting viruses (38–41).
Group 1 CD1-Restricted T Cells
Group 1 CD1-restricted T cells have been analyzed much less inten-
sively than NKT cells. They can be CD4+, CD8+, or double nega-
tive (DN) (42, 43). In vitro-studies revealed that after recognition 
of self or foreign lipid antigens group 1 CD1-restricted T  cells 
become cytoloytic and secrete large amounts of cytokines such as 
IFN-γ and TNF-α (44–46). These cytokines have a profound anti-
viral effect and play a pivotal role in controlling persistent virus 
infections (47). Self-reactive group 1 CD1-restricted T cells are 
common and the frequency is comparable to alloreactive T cells 
(estimated to be 1/10 to 1/300 of circulating T cells) (42, 48). They 
can induce TNF-α dependent DC maturation (49). Intriguingly, 
self-reactive CD1b-restricted T cells can acquire the phenotype 
of T helper 17 (Th17) cells and recruit neutrophils (50). The 
autoreactivity of group 1 CD1-resticted T  cells is enhanced by 
stimulation through pattern recognition receptors (PRRs) (51). 
It is probable that viruses also trigger activation of self-reactive 
group 1 CD1-restricted T cells through virus-sensing PRRs and 
that this contributes to antiviral immunity or virus-induced 
immunopathogenesis. This notion is supported by the finding 
that HHV-5, also called human cytomegalovirus (HCMV) can 
interfere with localization of group 1 CD1 molecules to the cell 
surface especially CD1b (52).
CD1d-Restricted T Cells
iNKT Cells
As part of the innate immune system iNKT  cells perform 
multiple effector functions rapidly after being activated. 
Human iNKT  cells comprise phenotypically and functionally 
distinct subsets: CD4+, a small fraction of CD4−CD8αα+ and 
DN cells (53). The CD4+ subset can produce Th2-type cytokines 
whereas both the CD4+ and CD4− subsets can secrete Th1-type 
cytokines and cytotoxic molecules such as perforin or granzyme 
B (54–56). The iNKT  cells can contribute to both protection 
from pathogenesis and enhancement of disease (57). In mice, 
functionally polarized subsets of iNKT cells are generated in the 
thymus. They secrete Th1-, Th2-, or Th17-like cytokines (NKT1, 
NKT2, and NKT17 subsets) similar to MHC class II-restricted 
CD4+ T  cells and innate lymphoid cells (58–60). In fact, these 
subsets and the corresponding MHC-restricted T  cell subsets 
share the same transcription factors that regulate their function 
(61). Further subsets of iNKT cells that are potentially relevant 
during viral infections have been defined: follicular helper-like 
iNKT  cells (62), IL-9-producing iNKT  cells (63), regulatory 
(Foxp3+) iNKT  cells (64, 65), and IL-10-producing iNKT  cells 
called NKT10 cells (66).
The iNKT cells can lyse CD1d+ target cells, mostly through 
the interaction between CD95 (Fas) and CD178 (FasL) (67, 68). 
Virus-infected cells are eliminated by iNKT  cells in a CD1d-
dependent manner (69). In line with this notion, iNKT cells limit 
the number of Epstein–Barr virus (EBV)-transformed human 
B cells in vitro by a mechanism requiring direct contact with EBV-
infected cells (70). EBV, a HHV that infects more than 90% of the 
human population worldwide, is associated with tumors, such as 
Burkitt lymphoma, Hodgkin disease, and lymphomas, in immu-
nosuppressed patients (71). The iNKT cell frequency in human 
tissue is very low (approximately 0.1% in peripheral blood and 
spleen) (72). Additionally, in contrast to mice iNKT cells are not 
enriched in the human liver (73, 74). This suggests that human 
iNKT cells may be more important in helping orchestrate the 
antiviral immune response rather than in killing virus-infected 
cells.
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There is ample evidence that iNKT  cells attract, stimulate, 
and regulate other innate cells with antiviral effector functions 
such as NK  cells and neutrophils (21, 22). NK  cells are found 
in most compartments of the human organism at a higher fre-
quency than iNKT cells and are critically involved in protection 
from persisting viruses (75, 76). The iNKT  cells transactivate 
NK cells through the release of IFN-γ in mice (77–80) or IL-2 
in humans (81). Moreover, iNKT cells can directly or indirectly 
recruit and activate neutrophils. These innate cells contribute to 
both antiviral defense and virus-induced immunopathogenesis 
(82–85). NK1.1-negative iNKT lymphocytes can directly recruit 
neutrophils through preferential IL-17 secretion (86, 87). The 
iNKT cells can also indirectly promote neutrophil responses by 
interacting with monocyte-derived DCs resulting in prolonged 
Ca+ influx and release of inflammatory mediators such as PGE2 
(88). In mice infected with murine cytomegalovirus (MCMV), a 
well-established model of persistent herpesvirus infection, IL-22 
secreted by iNKT  cells contributes to recruitment of antiviral 
neutrophils expressing TNF-related apoptosis-inducing ligand 
(TRAIL) (85). Moreover, iNKT cells can reverse the suppressive 
phenotype of neutrophils that is induced by acute-phase react-
ant serum amyloid A-1 (89). Vice versa, neutrophils may reduce 
inflammatory iNKT cell responses by a contact-dependent mecha-
nism thereby contributing to reduction of inflammation (90). 
These examples illustrate how intensely iNKT  cells and other 
innate immune cells cross-regulate each other.
Another important antiviral function of iNKT  cells is the 
regulation of adaptive immunity (91). For example, iNKT cells 
help B cells to proliferate and produce high titers of antibodies 
(92, 93). B  cells present bacterial glycolipids through CD1d to 
iNKT cells which in turn differentiate into follicular helper-like 
iNKT  cells that provide cognate help to B  cells (62, 94–96). 
Recent evidence suggests that iNKT  cells are also critical for 
production of specific antibodies during viral infections despite 
the absence of exogenous lipid antigens (97, 98). The underlying 
mechanism, however, is neither based on follicular helper-like 
iNKT cell differentiation nor CD1d-mediated cognate B cell help 
by iNKT cells but on tightly regulated early cytokine secretion 
by iNKT cells at the interfollicular area (97). On the other hand, 
iNKT  cells licensed by a specialized neutrophil subset restrict 
activation of autoreactive B  cells during inflammasome-driven 
inflammation through FasL (67).
In addition to helping B  cells, iNKT  cells promote T  cell 
responses directed against intracellular pathogens such as viruses 
(79, 99–103). This is accomplished by iNKT-mediated DC matu-
ration, which is of central importance for an efficient antiviral host 
defense (99, 104–106). It has also been reported that activated 
CD4−CD8αα+ iNKT cells curb expansion of antigen-stimulated 
conventional T cells by CD1d-dependent killing of DCs (107). 
Thus, iNKT cell subsets regulate adaptive immune responses at 
different stages.
The importance of crosstalk between iNKT cells and monocyte-
derived DCs is underlined by the observation that both cell 
types are programmed to migrate to inflamed peripheral tissue 
(55, 108–110). Many persistent viruses such as herpes simplex 
virus type 1 (HSV-1), HSV-2 and HCMV target monocyte-
derived DCs to induce apoptosis or impair antigen presentation 
through MHC class I molecules (111–113). As a consequence 
antiviral CD8+ T cells have to be activated by uninfected bystander 
DCs that take up apoptotic debris containing viral antigens and 
cross-present it through MHC class I molecules (114, 115). This 
cross-presentation, also called cross-priming, requires pathogen-
associated molecular patterns (PAMPs) and/or specialized subsets 
of Th cells that mature or “license” the cross-presenting DCs 
(116). It has been shown that uninfected DCs can be licensed for 
cross-priming by iNKT cells (117). On the other hand, iNKT cells 
suppress CD8+ T cell responses to viral proteins expressed in skin 
epithelial cells by blocking cross-priming in the draining lymph 
nodes (118). This suppressive iNKT cell effect may increase the 
persistence of viruses such as HPV and HSV-1 in the skin. The 
effect of iNKT  cells on CD8+ T  cell priming (activating versus 
inhibitory) may be dependent on the type of antigen and the 
requirement for CD4+ T cell helper epitopes (118).
A recent study has shown that iNKT cells release the brake on 
the adaptive immune response against influenza virus by inter-
fering with myeloid-derived suppressor cells (MDSCs) (119). 
MDSCs are in fact a heterogeneous population of myeloid pro-
genitor cells including immature DCs, immature macrophages, 
and granulocytes (120). The iNKT cells abolish the suppressive 
activity of MDSCs in a crosstalk that requires CD1d and CD40. 
The finding by De Santo et al. is important as MDSCs facilitate the 
development of persistent virus infections by impairing antiviral 
functions of T cells, NK cells, and APCs (121).
Type 2 NKT Cells
Evidence that type 2 NKT  cells play a protective role in virus 
infections came from a study that compared virus-induced 
disease severity between wild-type mice, Jα18 KO mice (lacking 
only type 1 NKT cells) and CD1d KO mice (lacking both type 1 
and type 2 NKT cells) (122). In comparison to iNKT cells little is 
known about the function of type 2 NKT cells due to the lack of 
suitable animal models and the difficulty in tracking this poorly 
defined cell type in vivo (41). However, there is evidence that type 
2 NKT cell subsets with distinct functional profiles exist (41, 123).
CLiNiCAL OBSeRvATiONS
A number of clinical observations suggest involvement of CD1-
restricted T  cells in either the control of persisting viruses or 
virus-induced immunopathogenesis.
Group 1 CD1-Restricted T Cells
Group 1 CD1-restricted T cells from patients with active tuber-
culosis expand after reexposure to cognate antigen similar to 
adaptive MHC-restricted T cells (124). In HIV-infected patients, 
CD1b-restricted T cells recognizing mycobacterial glycolipids are 
strongly reduced (125). The reduced frequency of mycobacteria-
specific CD1b-restricted T cells may contribute to the increased 
incidence of tuberculosis in this group. The kinetics of group 1 
CD1-restricted T cells stimulated by virus-induced self-lipids is 
not understood. Self-reactive group 1 CD1-restricted T cells show 
an adaptive-like population dynamics (42). It is possible but has 
not yet been proven that group 1 CD1-restricted T cell reacting 
to virus-induced stimulatory self-lipids expand in a similar way 
FiGURe 1 | Dynamics of CD1-restricted T cells after persistent virus 
infections. (A) Group 1 CD1-restricted T cells are thought to undergo clonal 
expansion in response to an acute infection followed by a contraction phase 
leaving an increased population of memory cells. (B) The frequency of 
invariant NKT (iNKT) cells in the blood is maintained at a stable level over time 
in individuals infected with human herpesviruses (HHVs) or human 
papillomavirus (HPV). Human immunodeficiency virus (HIV) infection results in 
a loss of iNKT cells and a decrease in functionality. Hepatitis B virus (HBV) 
and hepatitis C virus (HCV) may result in a decrease in iNKT cell frequency 
due to redistribution into the liver.
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(Figure  1A). On the other hand, self-reactive CD1b-restricted 
T cells have been described that are more like innate T cells (126). 
These cells may contribute to early antiviral host defense similar 
to iNKT cells.
CD1d-Restricted T Cells
Patients with defective iNKT  cell responses suffer from severe 
infection with HHVs (127). For example, boys with X-linked 
lymphoproliferative disorder have severely impaired iNKT  cell 
development and T cell function that results in life-threatening 
lymphoproliferation after primary infection with EBV or Kaposi’s 
sarcoma-associated herpesvirus (KSHV) (128–131). A similar 
disease was observed in girls with a homo zygous mutation in 
the IL-2-inducible T  cell kinase (ITK) gene on chromosome 
5q31–5q32 (132). Moreover, patients with profound iNKT  cell 
deficiency develop severe VZV-associated disease after vac-
cination with the live attenuated varicella vaccine (133, 134). 
Hermansky–Pudlak syndrome type 2, an autosomal recessive 
disease caused by mutations of the AP3B1 gene, encoding for the 
beta3A subunit of AP-3, also show reduced numbers of iNKT cells 
(135). Intriguingly, iNKT  cell numbers decrease regardless of 
the HIV-status in patients with multicentric Castleman disease 
(MCD), a rare polyclonal lymphoproliferative disorder that is 
associated with KSHV (136). This observation suggests that 
a deficiency in iNKT  cells contributes to the pathogenesis of 
KHSV-associated MCD. Although deficient iNKT  cells can be 
regarded as the common denominator of these primary immun-
deficiencies it has to be kept in mind that other immune cells are 
affected as well.
In humans with an intact immune system, distinct dynamics of 
circulating iNKT cells are observed after infection with different 
persisting viruses. The frequency of peripheral blood iNKT cells 
after infection with persisting viruses that establish latent infec-
tion such as HHVs and HPV remain unaltered (Figure 1B) (98). 
In contrast, it has been reported that the frequencies of circulating 
iNKT cells are significantly decreased during chronic HBV and 
HCV infection and recover during antiviral therapy (Figure 1B) 
(137, 138). This decrease may be due to trafficking of iNKT cells 
to the liver as intrahepatic enrichment of iNKT cells is observed 
in patients with chronic viral hepatitis (137). In another study, 
however, iNKT  cell frequencies between patients with chronic 
viral hepatitis and healthy individuals were not different (139). 
CD1d is strongly upregulated on hepatocytes and other liver cells 
during chronic viral hepatitis (137, 140). In fact, CD1d-restricted 
T cells contribute to virus-induced liver injury by killing hepato-
cytes and production of pro-inflammatory cytokines, which 
promote liver fibrosis and cirrhosis (74, 137, 141–144).
Several studies have shown that iNKT cells are depleted during 
HIV infection (145–152) (Figure 1B). The remaining iNKT cells 
display an exhausted phenotype with reduced functionality that 
may improve with early antiretroviral therapy (152–157). In 
fact, the level of iNKT  cell activation in HIV-infected patients 
is associated with disease progression markers and the number 
and functionality of iNKT cells are preserved in non-progressive 
HIV infection (155, 158). Intriguingly, both CD4+ and CD4− 
iNKT  cells are depleted in HIV-infected individuals (149) 
although CD4− iNKT cells are resistant to HIV infection (148, 
150). This could be due to apoptosis of uninfected bystander 
cells. Triggering of both extrinsic and intrinsic death pathways 
in T cells due to systemic immune activation has been described 
in many studies (159).
CD1-ReSTRiCTeD T CeLLS iN ANiMAL 
MODeLS OF PeRSiSTeNT viRUS 
iNFeCTiONS
Group 1 CD1-Restricted T Cells
The function of group 1 CD1-restricted T cells has proven dif-
ficult to address in vivo as laboratory mice do not express group 
1 CD1 molecules (160–162). In contrast, mice with a humanized 
immune system express human group 1 CD1 molecules (163) and 
open up a new avenue for studying human immune responses to 
viral pathogens (164). Similarly, human group 1 CD1 transgenic 
mice have recently been developed (126, 165, 166). Future stud-
ies have to investigate a possible role of group 1 CD1-restricted 
T  cells in persisting virus infections by using suitable animal 
models and tetramers.
CD1d-Restricted T Cells
The protective and pathogenic role of CD1d-restricted T  cells 
has been investigated in several animal models of persistent virus 
infections (see Table 1).
TABLe 1 | Studies of CD1-restricted T cells in animal models.
virus Animal model Key findings Reference
HSV-1 CD1d KO and  
Jα18 KO mice
Type 1 and type 2 NKT cells contribute to virus control and reduce lethality, neuroinvasion, size of  
lesions and levels of latency
(167, 168)
HSV-1 Jα18 KO mice iNKT cells are required for an IFN-γ driven subtype profile of HSV-1 specific antibodies (98)
HSV-2 CD1d KO mice CD1d KO mice develop a higher disease core after intravaginal HSV-2 infection (169)
HSV-2 C57BL/6 mice Intravaginal pre-treatment of C57BL/6 mice with αGalCer lowers the disease core and vaginal viral load (170)
MCMV Jα18 KO mice C57BL/6 mice lacking iNKT cells can control MCMV replication (172, 220)
MCMV Jα18 KO mice iNKT cells contribute significantly to innate control of MCMV in BALB/c mice (176)
MCMV CD1d KO and Jα18 KO mice NKT cells counteract MCMV-induced meyelosuppression (173)
HBV HBV transgenic mice αGalCer-induced release of IFN-γ and type I IFN from iNKT cells stops HBV replication in the liver (80)
HBV HBV transgenic mice Type 2 NKT cells are activated by HBV replication causing hepatitis (181)
HBV HBV transgenic mice Blockade of NKG2D prevents hepatitis mediated by type II NKT cells (182)
HBV Ad-HBV infected mice Type 2 NKT cells control HBV infection through sensing of HBV-induced self-lipids (180)
SIV Asian macaques SIV-induced NKT cell depletion inversely correlates with viral load (184)
SIV Asian macaques and sooty 
mangabeys
Dysfunctionality of NKT cells is associated with increased immune activation and loss of CD4+ T cells (185)
Ad-HBV, HBV-expressing adenoviral particles; HBV, hepatitis B virus; HSV-1, herpes simplex virus type 1; HSV-2, herpes simplex virus type 2; MCMV, mouse cytomegalovirus; SIV, 
simian immunodeficiency viruses; NKT, natural killer T; iNKT, invariant NKT.
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Herpesviral Infection
Studies in CD1d KO and iNKT  cell-deficient (Jα18 KO) mice 
indicate that CD1d-restricted T cells have a protective role after 
infection with HSV-1 (98, 167, 168) or HSV-2 (169). In addi-
tion, intravaginal pretreatment of C57BL/6 mice with αGalCer 
lowers HSV-2 disease and inhibits viral replication (170). One 
report did not confirm an antiviral role for NKT cells, most likely 
because mice were infected with a less virulent HSV-1 strain (171).
In mice infected with MCMV, activation of iNKT  cells by 
exogenous αGalCer reduces viral replication (172). Furthermore, 
it has been shown in the MCMV model that iNKT  cells can 
protect from MCMV-induced myelosuppression (173). In 
C57BL/6 mice NK  cells can compensate for iNKT deficiency 
(172, 174, 175) whereas in BALB/c mice NK cells are less well 
activated by MCMV and thus iNKT deficiency results in higher 
viral loads (176).
Chronic Viral Hepatitis
In contrast to HHVs, HBV, and HCV infect target cells with-
out causing cytopathic effects. Injection of αGalCer into HBV 
transgenic mice activates intrahepatic resident iNKT  cells and 
NK cells resulting in noncytopathic control of HBV replication 
through secretion of type I and II IFN (80, 177). Hepatocytes 
directly control iNKT cell homeostasis through modulating the 
balance between activating and non-activating lipids presented 
by CD1d molecules (178). Accordingly, iNKT  cells act as an 
early warning system for HBV infection, which profoundly alters 
lipid metabolism (179). For example, type 2 NKT cells recognize 
CD1d-bound lysophospholipids, antigenic self-lipids that are 
generated in hepatocytes by a HBV-induced secretory phospho-
lipase (180). The resulting activation of type 2 NKT  cells also 
leads to IL-12 mediated transactivation of iNKT cells and plays 
a pivotal role in virus control (180). However, type 2 NKT cells 
can also cause liver injury in HBV transgenic mice (181, 182). It 
has to be kept in mind that there are major differences between 
human and murine liver NKT  cells when extrapolating these 
results to humans (73, 74). Nevertheless, human NKT  cell 
lines are stimulated in a CD1d-dependent manner by human 
hepatocytes (180). Taken together, these findings support clini-
cal observations suggesting a role for CD1d-restricted T cells in 
antiviral immunity and virus-induced immunopathogenesis in 
human liver.
HIV Infection
In a humanized mouse model of HIV-1 infection activation of type 
2 NKT cells inhibits viral replication and prevents virus-induced 
pancytopenia (183). In Asian macaques, which develop acquired 
immunodeficiency syndrome (AIDS) during persistent simian 
immunodeficiency virus (SIV) infection, NKT  cell depletion 
inversely correlates with viral load (184). Comparative studies of 
Asian macaques and sooty mangabeys, which serve as a natural 
host and do not develop AIDS during persistent SIV infection, 
suggest that NKT cells protect from SIV-induced immune activa-
tion and immunodeficiency (185).
ACTivATiON OF CD1-ReSTRiCTeD  
T CeLLS
In contrast to other microbes such as bacteria, viruses have not 
been investigated with regard to CD1 ligands, although viral infec-
tion can stimulate CD1-restricted antiviral T cells. Activation of 
CD1-restricted T cells during viral infection could be triggered 
by CD1 molecules presenting antigenic self-lipids. In addition, 
CD1-independent mechanisms that activate CD1-restricted 
T cells such as cytokine release have been described.
Group 1 CD1-Restricted T Cells
Autoreactive group 1 CD1-restricted T  cells are stimulated by 
DCs that express group 1 CD1 molecules and present increased 
amounts of antigenic self-lipids upon activation by bacterial 
PAMPs through TLRs (186, 187). It is very likely but has not yet 
been shown that group 1 CD1-restricted autoreactive T cells are 
activated in a similar fashion during viral infections upon activa-
tion of DCs through virus-sensing PRRs.
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CD1d-Restricted T Cells
CD1d-Dependent Activation
The limited repertoire of microbial and endogenous ligands 
presented by CD1d is expanding (188–190). However, the 
identity of self-lipids presented during viral infection is still 
enigmatic. Stimulatory self-lipids could be channeled into 
the CD1d-restricted antigen presentation pathway by several 
distinct mechanisms. First, there is ample evidence that TLR 
stimulation increases CD1d presentation of antigenic self-lipids 
resulting in iNKT cell activation (191–197). Besides modulating 
the repertoire of self-lipids, viruses also increase CD1 surface 
expression through triggering PRRs (198). Second, viral invasion 
and inflammation is associated with pathological hypoxia that 
activates hypoxia-inducible factor (HIF), a “master regulator” of 
adaptive immune responses (199, 200). HIF alters lipid metabo-
lism in such a way that self-reactive NKT cells are activated (201, 
202). Third, viruses profoundly rewire host lipid metabolism and 
remodel lipid distribution to boost in a coordinated fashion viral 
entry, replication, assembly, and egress (203–208). Disturbance 
of the normal lipid trafficking patterns within the cell due to 
enveloped virus production (HHVs, HBV, HCV) or even naked 
virus (HPV) will allow access of otherwise sequestered lipids 
or altered lipids to the relevant CD1 presenting compartment. 
Furthermore, after assembly and release from the infected host 
cell the envelope of the newly built viral particle may carry the 
ligand with it and deliver it during infection to another host cell. 
Taken together, several distinct mechanisms facilitate CD1d-
dependent iNKT cell activation during different stages of the viral 
life cycle.
Of note, viral immune evasion mechanisms targeting other 
immune components may alert iNKT cells. For example, MHC 
class I downregulation by virus-encoded immunevasins induces 
CD1d upregulation and enhances NKT  cell activation (209). 
This finding is supported by other observations. First, low pH 
stripping of MHC class I molecules augments CD1d surface 
expression and activates iNKT  cells (210). Second, APCs from 
transporter associated with antigen presentation 1 (TAP1)-
deficient mice are defective in MHC class I antigen presentation 
but show an increased capacity to stimulate iNKT  cells (210, 
211). This reverse correlation between CD1d and MHC class I 
surface expression may enable iNKT  cells to detect the loss of 
MHC class I molecules, a situation called “missing self ” (212). 
The underlying mechanism is not yet fully understood but may 
involve masking of CD1d by MHC class I molecules on the cell 
surface (210). Increased iNKT  cell activation during persistent 
virus infections may also result from viral blockers inhibiting the 
autophagic machinery, which downregulates iNKT cell responses 
through CD1d internalization (213, 214).
CD1d-Independent Activation
CD1d-restricted T cells can also be stimulated independently of 
the TCR. First, there is ample evidence that pro-inflammatory 
cytokines (IL-12, IL-18, or type I IFN) released from APCs after 
stimulation through PRRs activate iNKT  cells predominantly 
in a CD1d-independent manner (215, 216). It may be that 
an initial CD1d-mediated TCR signal is still required (217). 
CD1d-independent iNKT cell activation was observed in mice 
infected with MCMV, and was driven by type I IFN and IL-12 
after DC stimulation (176, 218–220). The factors that determine 
whether pro-inflammatory cytokines are sufficient for activation 
of antiviral iNKT cells are unclear.
Second, engagement of NKG2D on NKT  cells results in 
CD1d-independent activation and subsequent killing of ligand-
expressing target cells (182, 221). NKG2D is an activating receptor 
expressed on CD4− iNKT cells and is triggered by stress ligands. 
The latter are upregulated during viral infections after stimulation 
of virus-sensing PRRs such as RIG-I and MDA-5 (222, 223). In 
addition, NKG2D can also co-stimulate TCR-mediated activa-
tion of CD4− iNKT cells (221).
Third, iNKT cells can be activated by apoptotic cells through 
TIM-1, a member of the T-cell immunoglobulin mucin (TIM) 
family of cell surface proteins (224). TIM-1 is constitutively 
expressed by NKT cells and serves as a receptor for phosphati-
dylserine, an important marker of cells undergoing apoptosis 
(225). This mode of iNKT cell activation may be relevant during 
persistent virus infections because viruses frequently drive their 
host cells into apoptosis (226).
viRAL evASiON OF CD1-ReSTRiCTeD  
T CeLLS
During the evolutionary arms race with the host immune system 
persisting viruses have developed multilayered defense strategies 
to interfere with antiviral CD1-restricted T  cells (17, 33, 35, 
36, 227). They target the CD1 antigen presentation machinery 
either on the transcriptional, posttranscriptional, or posttrans-
lational level.
Group 1 CD1-Restricted T Cells
The group 1 CD1 molecules are expressed on professional APCs 
in response to certain cytokines such as granulocyte-macrophage 
colony-stimulating factor (228). The anti-inflammatory cytokine 
IL-10 prevents upregulation of group 1 CD1 molecules on profes-
sional APCs such as monocyte-derived DCs (229–231). In fact, 
the activity of IL-10 is crucial for establishing viral persistence 
(232). Large DNA viruses such as herpesviruses have acquired 
numerous genes from their host including viral homologs of 
IL-10 (vIL-10) to subvert the host immune response (233, 234). 
For example, vIL-10 from HCMV and EBV not only prevent 
upregulation of MHC class I/II molecules but also group 1 CD1 
molecules (52, 235). Recent reports suggest that vIL-10 strongly 
induces the expression of its cellular counterpart in monocyte-
derived cells thereby potentiating its immunomodulatory effect 
(236, 237). In addition, viral proteins with no homology to cel-
lular proteins such as HCMV-encoded pUL11 or EBV-encoded 
latent membrane protein 1 highjack cellular signaling pathways 
to induce expression of cellular IL-10 (238, 239).
Group 1 CD1 molecules are downregulated from the cell sur-
face during the early phase of HCMV infection with CD1b being 
especially sensitive to this effect (52). This block is not performed 
by known HCMV-encoded MHC class I-blocking molecules and 
results in the intracellular accumulation of group 1 CD1 molecules 
FiGURe 2 | Evasion of CD1d antigen presentation. Persisting viruses evade invariant NKT (iNKT) cell activation by interfering with CD1d biosynthesis and CD1d 
trafficking. (1) CD1d gene transcription is downregulated by increased binding of Epstein–Barr virus (EBV)-encoded lymphoid enhancer-binding factor 1 (LEF-1) to 
the distal region of the CD1d promotor. (2) Viral host shutoff factors such as EBV BGLF5, an early lytic phase protein, inhibit protein synthesis by degrading mRNA. 
(3) Human papillomavirus (HPV) E5 translocates CD1d into the cytosol for proteasomal degradation. (4) EBV gp150 provides an abundantly sialylated glycan shield 
for CD1d on the cell surface preventing recognition by iNKT cells. (5) Herpes simplex virus type 1 (HSV-1) glycoprotein B/US3 and human immunodeficiency virus 
(HIV) negative factor (Nef) redirect CD1d to the trans-Golgi network (TGN). (6) In contrast, HIV Nef retains CD1d in the early endosome (EE). (7) Kaposi’s sarcoma-
associated herpesvirus (KSHV) K3 redirects CD1d from the late endosome (LE) to the lysosome.
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(52). The underlying mechanism has not yet been described. In 
addition, HIV-1 negative factor (Nef) downregulates CD1a after 
infection of immature DCs with HIV-1 and impairs stimulation 
of CD1a-restricted T cells (240, 241). In order to modulate host 
membrane trafficking pathways HIV-1 Nef has to interact with 
various host proteins through distinct motifs (242). Nef-mediated 
CD1a downregulation might require the interaction of Nef with 
hematopoietic cell kinase and p21-activated kinase 2, which are 
both expressed in immature DCs (241). Collectively, these find-
ings support the idea that group 1 CD1 molecules contribute to 
lipid-driven antiviral immune responses.
CD1d-Restricted T Cells
Viral Downregulation of CD1d Gene Transcription
In contrast to group 1 CD1 molecules, CD1d is constitutively 
expressed not only in myeloid cells such as B cells, macrophages, 
and DCs and but also in epithelial tissue. Latent EBV infec-
tion that is associated with transformation of B  cells results in 
complete shutdown of CD1d mRNA expression and the lack of 
iNKT  cell activation (70). This is due to increased binding of 
lymphoid enhancer-binding factor 1 to the distal region of the 
CD1d promotor (Figure  2). Moreover, CD1d transcription is 
downregulated during severe primary HCMV infection (243).
Virus-Induced Degradation of CD1d mRNA
Replicating α- and γ-herpesviruses induce global mRNA degra-
dation to shut off host protein synthesis and reallocate cellular 
resources to their own need by different mechanisms (244). It 
has been shown that EBV-encoded shutoff protein BGLF5, a lytic 
phase protein, downregulates multiple immune components 
including CD1d (Figure 2) (245, 246).
Viral Interference With Trafficking of CD1d Molecules
After translation, CD1 heavy chains bind to β2-microglobulin 
and are loaded with self-lipids in the endoplasmic reticulum 
(ER). This trimeric complex travels then to the cell surface 
through the secretory pathway. Subsequently, a tyrosine motif 
within their cytoplasmic tail enables human CD1 molecules 
to bind the μ-subunit of adaptor protein complex (AP)-2 
(CD1b-d) and AP-3 (CD1b and murine CD1d). In contrast, 
CD1a lacks AP-2 and AP-3 sorting motifs. Because of these 
differences CD1 molecules traffic through distinct intracellular 
compartments for acquiring lipids and present these lipids to 
CD1-restricted T  cells (247–249). Persistent viruses utilize 
various posttranslational mechanisms to interfere with antigen 
presentation through CD1d molecules in different cellular 
compartments.
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Virus-Induced Proteasomal Degradation of CD1d in 
the Cytosol
HPV subverts immune responses through expression of E5 
(250). Clinical samples of HPV-infected cervical epithelium show 
decreased CD1d expression (251). Further analysis of transfected 
cell lines revealed that HPV E5 interacts with calnexin, a chaper-
one involved in CD1d folding in the ER, and finally targets CD1d 
to the cytosolic proteolytic pathway (Figure 2) (251).
Viral Shielding of Surface CD1d Molecules
A novel broadly acting mechanism of herpesviral subversion of 
antigen presentation has been discovered recently (252). EBV-
encoded gp150, which is heavily glycosylated and expressed in 
the late phase of EBV replication, inhibits antigen presentation by 
MHC class I and II as well as CD1d molecules. The EBV-encoded 
gp150 does not interfere with recycling of CD1d molecules 
but prevents their detection by iNKT  cells on the cell surface 
through an abundantly sialylated glycan shield (Figure 2) (252). 
Of interest, the Ebola virus glycoprotein masks MHC class I 
molecules by a similar mechanism but an effect on CD1d has not 
yet been tested (253). Further studies have to elucidate whether 
other herpesviruses have developed are similar strategy to mask 
antigen-presenting molecules on the cell surface.
Viral Modulation of CD1d Recycling
Persisting viruses can also subvert CD1 antigen presentation 
by interfering with CD1 recycling. For example, CD1d surface 
expression is downregulated during productive infection with 
HHVs such as HSV-1 (209, 254) and KSHV (255). This effect 
was dependent on the viral titer used for infection of CD1d-
expressing cells (209).
Further attempts identified several viral proteins interfering 
with CD1d recycling. For example, KSHV-encoded modulator of 
immune recognition proteins 1 and 2 (also known as K3 and K5) 
function as membrane-bound E3-ubiquitin ligases and reduce 
expression of a number of immunologically important surface 
molecules including MHC class I and CD1d (256). In fact, K3 and 
K5 have been pilfered from the host genome and belong to the 
Membrane Associated RING-CH family of E3 ligase (MARCH) 
proteins. They reroute both MHC class I and CD1d to the lyso-
somal compartment by ubiquitinylating a unique lysine residue 
on the cytoplasmic tail (Figure 2) (255). In contrast to MHC class I, 
however, the CD1d complexes are resistant to lysosomal degrada-
tion result ing in reduced CD1d levels on KSHV-infected B cells 
although the total cellular amount of CD1d is not altered (255).
A recent study shows that CD1d molecules on the APC surface 
build nanoclusters and that these structures are important for 
iNKT  cell activation (257). Intriguingly, the actin cytoskeleton 
prevents CD1d nanoclustering (257). This finding is in accord-
ance with a previous study showing that disruption of actin 
filaments increases CD1d antigen presentation (258). It may 
also explain why HSV-1 lacking VP22 (UL49), a viral tegument 
protein that stabilizes microtubules, lacks the ability to inhibit 
CD1d recycling (259). Although VP22 is necessary for HSV-1 
induced CD1d downregulation, other viral proteins are addition-
ally required. The type II kinesin motor protein KIF3A, which 
transports proteins along the microtubule network, is necessary 
for CD1d surface expression (260). Of relevance, KIF3A is phos-
phorylated by US3, a HSV-1 encoded protein that induces down-
regulation of CD1d by suppressing its recycling (261). Another 
HSV-1 protein, glycoprotein B (gB), binds to CD1d within the 
ER and remains stably associated throughout CD1d trafficking 
(261). Both US3 and gB seem to be required for relocalization of 
CD1d to the trans-Golgi network (TGN) thereby reducing CD1d 
surface expression and iNKT cell activation (Figure 2) (261). In 
contrast, a previous study has reported that CD1d is trapped in 
lysome-like structures during HSV-1 infection (254). Similarly, 
another study reported that CD1d molecules are degraded in the 
lysosomes after HSV-1 induced phosphorylation of a dual residue 
motif (T322/S323) in the cytoplasmic tail of CD1d (262, 263). 
However, under normal conditions CD1d complexes are resistant 
to lysosomal degradation (255, 264).
HIV-1 encodes two proteins, Nef and viral protein U (Vpu) 
which target numerous immunologically important surface 
molecules including CD1d (265). In HIV-1 infected DCs, Vpu 
neither induces endocytosis nor rapid degradation but sup-
presses CD1d recycling by retaining CD1d in the early endosome 
(196, 266, 267). In contrast, Nef increases CD1d internalization 
and re-localizes CD1d molecules to the TGN (196, 268, 269). 
Thus, Vpu and Nef interfere with iNKT cell activation by com-
plementary mechanisms (Figure 2). As a result, the capacity of 
HIV-1 infected DCs to stimulate iNKT cells is impaired (196).
The unique short (US) region of HCMV encodes several 
proteins including US2 and US11 that interfere with antigen pres-
entation through MHC class I molecules (270). US2 and US11 
induce rapid translocation of MHC class I heavy chains from the 
ER into the cytosol and subsequent degradation by the protea-
some (271, 272). US2 and US11 also physically interact with 
CD1d but do not downregulate CD1d surface expression (273, 
274). However, reduced activation of iNKT cells after stimulation 
with αGalCer-pulsed US2-expressing APCs has been reported 
but the underlying mechanism is unclear (274).
Viral Disruption of the iNKT Cell–DC Axis
The bidirectional interaction between DCs and iNKT cells is cru-
cial for an efficient antiviral immune response (28, 275). During 
infection triggering of a combination of PRRs stimulates IL-12 
release from DCs and increases the presentation of antigenic 
self-lipids by CD1d (191, 195, 197). In fact, signaling through 
PRRs inhibits degradation of glyosylceramides in the lysosome 
thereby increasing the amount of lipids that stimulate iNKT cells 
(193, 276). Once activated iNKT  cells further enhance IL-12 
production by DCs through CD40–CD40 ligand stimulation. 
This amplification loop then results in NK  cell transactivation 
and increased responses of MHC-restricted CD4+ as well as CD8+ 
T  cell responses. Persisting viruses such as HHVs use several 
different strategies to blunt DC function (277). For example, 
VZV interferes with TLR signaling in DCs thereby decreasing 
IL-12 production (278). Moreover, herpesviral IL-10 homologs 
can decrease the ability of uninfected DCs to secrete IL-12 (234). 
Virus-infected DCs that do not produce biologically active 
IL-12 fail to activate the antiviral functions of iNKT cells (279). 
Moreover, HCMV-infected DCs upregulate on the surface death 
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ligands such as TRAIL that kill T cells (113). Taken together, it 
is likely that multilayered viral countermeasures severely impair 
activation and function of iNKT  cells thereby disrupting the 
important iNKT cell–DC axis.
Viral Interference With CD1d-Independent  
Activation of CD1d-Restricted T Cells
Persistent viruses such as HHVs also interfere with NKG2D 
ligand upregulation on virus-infected cells thereby reducing the 
likelihood of NKG2D-mediated activation of antiviral iNKT and 
type 2 NKT cells (280, 281). Moreover, HSV-1-infected keratino-
cytes block cytokine-dependent activation of iNKT cells (282).
Virus-Induced Functional Impairment  
of CD1d-Restricted T Cells
Persisting viruses not only target CD1 antigen presentation and 
interfere with activation of CD1-restricted T  cells but can also 
induce a state of unresponsiveness in CD1-restricted T cells. It 
has been demonstrated in  vitro that HSV-1-infected keratino-
cytes impair TCR signaling in iNKT cells in a contact-dependent 
manner (282). In contrast to DCs, CD1d is not downregulated 
on keratinocytes after infection with HSV-1. This finding nicely 
illustrates that depending on the infected cell type one and the 
same virus use different strategies to evade CD1d-restricted 
T cell responses. Moreover, iNKT cells from patients with KSHV-
associated MCD, a severe B-cell lymphoproliferative disorder, 
show impaired proliferation when stimulated with αGalCer 
(136). This hyporeactive state is indicative of virus-induced 
iNKT  cell anergy or exhaustion. In accordance, induction of 
anergy in iNKT cells has been described in many reports and is 
required for prevention of uncontrolled inflammation and tissue 
destruction (283). On the other hand, it also allows viruses to 
replicate and spread more efficiently. The underlying mechanisms 
of virus-induced iNKT cell anergy are unknown but may involve 
viral modulation of costimulatory molecules and other signaling 
molecules on APCs (284).
Recently, a regulatory iNKT cell subset called NKT10 has been 
described that bear similarities to Tregs (66). Tregs suppress pro-
tective immune responses thereby supporting virus persistence 
and at the same time also reducing the inflammation-mediated 
tissue damage (285). The NKT10 cells occur naturally in mice 
and humans and expand after stimulation (66). It would be 
interesting to investigate whether persisting viruses increase the 
frequency and activity of NKT10 cells to curb antiviral immune 
responses.
CONCLUSiON AND FUTURe DiReCTiONS
The risk for the host in terms of severe disease from a persistent 
virus infection ranges from low in case of well-adapted viruses 
such as the HHVs to ineluctable in case of a recent émigré such 
as HIV-1. CD1-reactive cells play a significant role in this process. 
Although the role of self-reactive NKT cells in antiviral immunity 
and immunopathogenesis has been analyzed in the clinical set-
ting and in experimental models, it is unclear how group 1 CD1-
restricted T cells contribute to antiviral immunity. Future efforts 
should define in detail the antigenic self-lipids that are induced 
and loaded on CD1 molecules during viral infections and how 
they program antiviral immunity. This knowledge can then be 
harnessed to develop novel vaccines and adjuvants for protection 
from persistent virus infection.
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